These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 35265754)

  • 1. Mitochondria-targeted drugs for diabetic kidney disease.
    Mima A
    Heliyon; 2022 Feb; 8(2):e08878. PubMed ID: 35265754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxidative Stress: A Culprit in the Progression of Diabetic Kidney Disease.
    Wang N; Zhang C
    Antioxidants (Basel); 2024 Apr; 13(4):. PubMed ID: 38671903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxidative stress as a culprit in diabetic kidney disease.
    Su S; Ma Z; Wu H; Xu Z; Yi H
    Life Sci; 2023 Jun; 322():121661. PubMed ID: 37028547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitochondrial Regulation of Diabetic Kidney Disease.
    Galvan DL; Mise K; Danesh FR
    Front Med (Lausanne); 2021; 8():745279. PubMed ID: 34646847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review.
    Alicic RZ; Johnson EJ; Tuttle KR
    Am J Kidney Dis; 2018 Aug; 72(2):267-277. PubMed ID: 29866460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chinese botanical drugs targeting mitophagy to alleviate diabetic kidney disease, a comprehensive review.
    Ma L; Li J; Zhang X; Zhang W; Jiang C; Yang B; Yang H
    Front Pharmacol; 2024; 15():1360179. PubMed ID: 38803440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease.
    Mima A
    J Diabetes Complications; 2018 Jul; 32(7):720-725. PubMed ID: 29880432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcription of MRPL12 regulated by Nrf2 contributes to the mitochondrial dysfunction in diabetic kidney disease.
    Gu X; Liu Y; Wang N; Zhen J; Zhang B; Hou S; Cui Z; Wan Q; Feng H
    Free Radic Biol Med; 2021 Feb; 164():329-340. PubMed ID: 33444714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitochondrial dysfunction in diabetic kidney disease.
    Wei PZ; Szeto CC
    Clin Chim Acta; 2019 Sep; 496():108-116. PubMed ID: 31276635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitochondrial dynamics and diabetic kidney disease: Missing pieces for the puzzle of therapeutic approaches.
    Narongkiatikhun P; Chattipakorn SC; Chattipakorn N
    J Cell Mol Med; 2022 Jan; 26(2):249-273. PubMed ID: 34889040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Mitochondria-Targeted Metabolic Tubular Injury in Diabetic Kidney Disease.
    Jiang H; Shao X; Jia S; Qu L; Weng C; Shen X; Wang Y; Huang H; Wang Y; Wang C; Feng S; Wang M; Feng H; Geekiyanage S; Davidson AJ; Chen J
    Cell Physiol Biochem; 2019; 52(2):156-171. PubMed ID: 30816665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucose- and Non-Glucose-Induced Mitochondrial Dysfunction in Diabetic Kidney Disease.
    Ito M; Gurumani MZ; Merscher S; Fornoni A
    Biomolecules; 2022 Feb; 12(3):. PubMed ID: 35327540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic mechanism and clinical application of Chinese herbal medicine against diabetic kidney disease.
    Chen DQ; Wu J; Li P
    Front Pharmacol; 2022; 13():1055296. PubMed ID: 36408255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Diabetic Kidney Disease: Current and Future.
    Yamazaki T; Mimura I; Tanaka T; Nangaku M
    Diabetes Metab J; 2021 Jan; 45(1):11-26. PubMed ID: 33508907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets.
    Barrera-Chimal J; Jaisser F
    Diabetes Obes Metab; 2020 Apr; 22 Suppl 1():16-31. PubMed ID: 32267077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on diagnosis, pathophysiology, and management of diabetic kidney disease.
    Sugahara M; Pak WLW; Tanaka T; Tang SCW; Nangaku M
    Nephrology (Carlton); 2021 Jun; 26(6):491-500. PubMed ID: 33550672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic kidney disease in type 2 diabetes: Implications for managing glycaemic control, cardiovascular and renal risk.
    Stephens JW; Brown KE; Min T
    Diabetes Obes Metab; 2020 Apr; 22 Suppl 1():32-45. PubMed ID: 32267078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic Targeting of SGLT2: A New Era in the Treatment of Diabetes and Diabetic Kidney Disease.
    Shaffner J; Chen B; Malhotra DK; Dworkin LD; Gong R
    Front Endocrinol (Lausanne); 2021; 12():749010. PubMed ID: 34790170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies.
    Warren AM; Knudsen ST; Cooper ME
    Expert Opin Ther Targets; 2019 Jul; 23(7):579-591. PubMed ID: 31154867
    [No Abstract]   [Full Text] [Related]  

  • 20. Recent Advances in the Emerging Therapeutic Strategies for Diabetic Kidney Diseases.
    Huang W; Chen YY; Li ZQ; He FF; Zhang C
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.